Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 130 of 1,261
  1. US 11931453

    Drug delivery device

    Nano Precision Medical, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  2. US 11932633

    KRas G12C inhibitors

    Mirati Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  3. US 11931337

    Compound antioxidant preparation for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof

    China Agricultural University · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  4. US 11931399

    Compositions and methods for dengue virus chimeric constructions in vaccines

    Takeda Vaccines, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  5. US 11931463

    All-in-one fixed-dose combination for treating Helicobacter pylori infection

    RedHill Biopharma Ltd. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  6. US 11931421

    Muscle targeting complexes and formulations for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  7. US 11931354

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  8. US 11932856

    RNA targeting of mutations via suppressor tRNAs and deaminases

    The Regents of the University of California · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  9. US 11932726

    Method of making releasable polymeric reagents

    Nektar Therapeutics · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  10. US 11932852

    Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

    Benitec IP Holdings Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  11. US 11932851

    Exon skipping compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  12. US 11932695

    Modified antibodies and related compounds, compositions and methods of use

    Sensei Biotherapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  13. US 11932692

    Methods of treating cancer pain by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  14. US 11932688

    Treatment for neoplastic diseases

    XBIOTECH INC. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  15. WO 2024052517

    USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE

    BAYER AG [DE] · Granted Mar 14, 2024 · Expires Mar 9, 2044

    granted
  16. KR 20240034693

    이량체 조영제의 제조

    BRACCO IMAGING SPA [IT] · Granted Mar 14, 2024 · Expires Mar 9, 2044

    granted
  17. US 11926830

    Modulators of Complement Factor B

    Ionis Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  18. US 11926828

    Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

    Phio Pharmaceuticals Corp. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  19. US 11926824

    miRNA biogenesis in exosomes for diagnosis and therapy

    The Board of Regents of the University of Texas System · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  20. US 11926825

    Compounds and methods for reducing ATXN2 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  21. US 11925689

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Serina Therapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  22. US 11925663

    Methods of managing tumor flare in adoptive immunotherapy

    Atara Biotherapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  23. US 11925649

    Treatments for diabetic neuropathy

    The Regents of the University of California · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  24. US 11925629

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.